(Q44534045)

English

An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer

scientific article published in August 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

author name string

Oliver Sartor

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Martin K Dineen

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Ramon Perez-Marreno

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Franklin M Chu

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Graham J Carron

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Robert C Tyler

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

language of work or name

0 references

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

319-323

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent androgen suppression in the management of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Absence of rapid desensitization of the mouse gonadotropin-releasing hormone receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of Gonadotropin-Releasing Hormone Receptor Signaling by Expression of a Splice Variant of the Human Receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Diversity and selectivity of receptor-G protein interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms mediating multiple physiological responses to gonadotropin-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional consequences of the phosphorylation of the gonadotropin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900330-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(03)00330-3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44534045&oldid=2027043545"